Apaziquone
Phase 3Small molecule
Spectrum Pharmaceuticals, IncApaziquone is one of 54 small molecule programs targeting Bladder Tumor. It is currently in Phase 3.
2
Indications
6
Total Trials
0
Active Trials
53
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
378 competitors in Bladder Cancer
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 3
Taxol
TevaPhase 3
Padcev
PfizerPhase 3
Taxotere
AAvyxa
Phase 3
Entereg
Merck & Co.Phase 3
Mitomycin C
GGynecologic Oncology Group
Phase 3
Bacillus Calmette-Guérin
Bristol-Myers SquibbPhase 3
Sacituzumab Tirumotecan
Merck & Co.Phase 3
TAR-200
Johnson & JohnsonPhase 3
Bacillus Calmette-Guerin
AstraZenecaPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Bladder Cancer5 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Apaziquone. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details